Skip to main content
Eckhard Thiel on Muck Rack

Eckhard Thiel

As seen in: Journal of Clinical Oncology, Alfelder Zeitung
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Eckhard

Contact Eckhard, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Entscheidung sollte korrigiert werden

|
By Eckhard Thiel
| Alfelder Zeitung Verified
Veröffentlichung online am 08.08.2024 um 13:35:18 Uhr, zuletzt geändert am 08.08.2024 um 13:35:24 Uhr Entscheidung sollte korrigiert werden 2024-08-08 13:33:05 Zum Artikel „Tradition endet nach 122 Jahren“ in der AZ vom 29. Juli Die SB-Stelle der Deustchen Bank zieht in die Kurze Straße 9 bis 11. Foto: Ulrich Meinhard (Archiv) Artikel anhören (01:15 min) Der Bericht bezüglich der Deutschen Bank (Finanzagentur) hat mich doch sehr verwundert.
Open in Who Shared Issue with article?

Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma

|
By Christian Schmidt, Peter Martus, Uwe Schlegel, Ulrich Herrlinger, Martin Dreyling, Luisa von Baumgarten, Antonio Pezzutto, Thomas Grobosch, Sied Kebir, Eckhard Thiel
| Journal of Clinical Oncology Verified
Results Thirty-seven eligible patients (median age, 70 years) were included whose median time since their last treatment was 3.9 months (range, 0.1 to 14.6 months). Complete response was seen in five patients (13.5%), complete response unconfirmed in three (8%), and partial response in 12 (32.4%) for an overall response rate of 54%. Median progression-free survival was 2.1 months (95% CI, 1.1 to 3.0 months).
Open in Who Shared Issue with article?

Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!

|
By Marc C. Chamberlain, Eckhard Thiel, Nancy Doolittle, Agnieszka Korfel, Ed Neuwelt
| Journal of Clinical Oncology Verified
The prognosis of secondary CNS involvement in systemic lymphomas (secondary CNS lymphoma, SCNSL) is poor, and the optimal treatment remains to be established. Because of the rarity of SCNSL and the lack of prospective trials, the level of evidence guiding therapy is low. Limited data suggest that intensive systemic chemotherapy, followed by high-dose chemotherapy and autologous stem-cell transplant (HD-ASCT), is the only potentially curative approach.
Open in Who Shared Issue with article?
See all 3 articles